This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated